TNF and COVID-19: In contrast, in accordance with previous studies that found that the respective treatments do not significantly impair COVID-19 vaccination efficacy, we observed a decrease in CFRs for patients under anti-TNFα (Dimopoulou et al., 2022; Pri-Paz Basson et al., 2022; Venerito et al., 2022), JAK inhibitor (Winthrop et al., 2016; Mortezavi et al., 2021; Pri-Paz Basson et al., 2022), or thalidomide analog (Jenner et al., 2021) treatment.